Tab. Hemorif DS

COMPOSITION
Hemorif® DS Tablet : Each film coated tablet contains Diosmin BP 900 mg & Hesperidin
USP 100 mg.
PHARMACOLOGY
Hemorif® DS is a phlebotonic drug and a vascular protecting agent. It reinforces venous
tone by prolonging the activity of parietal noradrenaline. Thus decreases venous
capacitance, venous distensibility, and venous emptying time. Hemorif® DS protects the
microcirculation by fighting the microcirculation damaging process; It combats venous
inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting
the release of inflammatory mediators, principally free radicals and prostaglandin. Thus
Hemorif® DS normalizes capillary permeability and strengthens capillary resistance.
Hemorif® DS acts on the lymphatic system, It improves lymphatic drainage by
increasing lymph flow and lymph oncotic pressure.
INDICATION
Used for poor circulation in the legs (Chronic Venous Insufficiency, CVI), hemorrhoids, leg
ulcers from poor circulation (venous stasis ulcers), also have some evidence for the
treatment of bleeding gums, bleeding/hemorrhage in the eye, preventing damage to
the liver, varicose veins).
DOSAGE & ADMINISTRATION
Acute Hemorrhoid: 1 tablet thrice daily for first 4 days, followed by 1 tablet twice daily
for 3 days & then 1 tablet once daily as maintenance dose.
Relapse of Internal Hemorrhoid & Chronic Hemorrhoid: 1 tablet once daily for 3 months.
CVI: 1 tablet once daily for 2-6 months.
Leg Wounds: 1 tablet once daily for 2 months.
WARNING & CONTRAINDICATION
CVI and its complications should be diagnosed and management monitored by a
physician. It is contraindicated for anyone having a hypersensitivity to any ingredient in
the product.
ADVERSE EFFECTS
The most common adverse reactions reported in subjects receiving combination
therapy were gastrointestinal disturbances, headache, rash, cramps in lower limb,
phlebitis, venous thrombosis
PATIENTS WITH CANCER
Diosmin (up to 900 mg/day) has been administered to a small number of breast
cancer patients who were experiencing lymphedema following surgical and
nodal irradiation treatment with resultant reduction of arm edema but no effect
on the cancer. Animal studies and more than 20 years of clinical use in Europe
have not found any evidence of carcinogenicity or mutagenicity when the
components of Diosmin+Hesperidin are used as recommended. As a precaution,
Diosmin+Hesperidin is not recommended for patients with a history of cancer
since no specific studies have been performed in this population.
DRUG INTERACTION
No evidence of drug incompatibility (drug interaction) has been reported in
clinical trials.
USE IN PREGNANCY & LACTATION
Pregnant Women: Experimental studies have not shown any teratogenic effect in
animals. In human beings, no harmful effect has so far been reported. Nursing
Women: In the absence of data concerning excretion into breast milk, breast
feeding is not recommended during treatment.
STORAGE
Store below 30o C, protect from light & moisture. Keep medicines away from
children.
HOW SUPPLIED
Box contains 30’ tablets in blister pack.